The RPF Rare Disease Group have recently completed a patient focused online study to understand the un-met medical need of patients with retroperitoneal fibrosis. All entries were anonymous. The results of the survey were presented at UK Kidney Week 2017.

Fred Tam is the chief investigator of the randomized controlled trial of Syk inhibitor in IgA nephropathy. He has received research project grants from AstraZeneca Limited, Baxter Bioscience, Boehringer Ingelheim Limited and GSK, and has consultancy agreements with Baxter Bioscience, MedImmune and Rigel Pharmaceuticals.

Retroperitoneal Fibrosis RDG Version 7 updated April 2018
Written by the Retroperitoneal Fibrosis Rare Disease Group